Development of oil-based gels as versatile drug delivery systems for pediatric applications

Administering medicines to 0- to 5-year-old children in a resource-limited environment requires dosage forms that circumvent swallowing solids, avoid on-field reconstitution, and are thermostable, cheap, versatile, and taste masking. We present a strategy that stands to solve this multifaceted probl...

Full description

Saved in:
Bibliographic Details
Published in:Science advances Vol. 8; no. 21; p. eabm8478
Main Authors: Kirtane, Ameya R, Karavasili, Christina, Wahane, Aniket, Freitas, Dylan, Booz, Katelyn, Le, Dao Thi Hong, Hua, Tiffany, Scala, Stephen, Lopes, Aaron, Hess, Kaitlyn, Collins, Joy, Tamang, Siddartha, Ishida, Keiko, Kuosmanen, Johannes L P, Rajesh, Netra Unni, Phan, Nhi V, Li, Junwei, Krogmann, Annlyse, Lennerz, Jochen K, Hayward, Alison, Langer, Robert, Traverso, Giovanni
Format: Journal Article
Language:English
Published: United States American Association for the Advancement of Science 27-05-2022
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Administering medicines to 0- to 5-year-old children in a resource-limited environment requires dosage forms that circumvent swallowing solids, avoid on-field reconstitution, and are thermostable, cheap, versatile, and taste masking. We present a strategy that stands to solve this multifaceted problem. As many drugs lack adequate water solubility, our formulations used oils, whose textures could be modified with gelling agents to form "oleogels." In a clinical study, we showed that the oleogels can be formulated to be as fluid as thickened beverages and as stiff as yogurt puddings. In swine, oleogels could deliver four drugs ranging three orders of magnitude in their water solubilities and two orders of magnitude in their partition coefficients. Oleogels could be stabilized at 40°C for prolonged durations and used without redispersion. Last, we developed a macrofluidic system enabling fixed and metered dosing. We anticipate that this platform could be adopted for pediatric dosing, palliative care, and gastrointestinal disease applications.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Boeing Company, Herndon, VA 20170, USA.
These authors contributed equally to this work.
ISSN:2375-2548
2375-2548
DOI:10.1126/sciadv.abm8478